Document Detail


Retrospective cohort study evaluating exenatide twice daily and long-acting insulin analogs in a Veterans Health Administration population with type 2 diabetes.
MedLine Citation:
PMID:  25059703     Owner:  NLM     Status:  Publisher    
Abstract/OtherAbstract:
AIM: This was a retrospective cohort study that evaluated the differences in glycated haemoglobin (HbA1c) and body mass index (BMI) in veterans with type 2 diabetes mellitus (T2DM), prescribed exenatide twice daily (BID) versus long-acting insulin analog (LAIA) two years after initiation in the United States (US) veteran population.
MATERIALS AND METHODS: Patients were included if they were≥18 years old with T2DM, and initiated exenatide BID or LAIA at the Veterans Health Administration between January 1, 2006 and December 31, 2010. Multivariate models were used to evaluate the changes in HbA1c and BMI between groups, controlling for potential confounders. Logistic regression was used to evaluate the odds of achieving≥0.5% HbA1c reduction based on baseline HbA1c stratifications: low,<7%; moderate, 7% to<9%; and high,≥9%.
RESULTS: A total of 446 exenatide BID and 51,531 LAIA patients met inclusion/exclusion criteria. On average, exenatide BID patients were significantly older (64 versus 60 years) with a higher BMI (37.8 versus 32.9kg/m(2)). Baseline HbA1c was 8.2% and 8.8% for exenatide BID and LAIA patients, respectively (P<0.001); otherwise, patients were similar for all other characteristics. Exenatide BID treatment was significantly associated with a 0.32% (95%CI: 0.18-0.47%) greater reduction in HbA1c at two years compared with LAIA. Similar findings were observed for BMI reduction (0.68kg/m(2); 95%CI: 0.42-0.95kg/m(2)). Exenatide BID patients with moderate baseline HbA1c had significantly higher odds of achieving≥0.5% HbA1c reduction compared with LAIA patients (OR=1.5; 95%CI: 1.2-2.0).
CONCLUSIONS: Veterans treated with exenatide BID had significantly greater reduction in HbA1c and BMI compared with patients treated with LAIA patients two years after initiation.
Authors:
M Bounthavong; J N Tran; S Golshan; N F Piland; C M Morello; A Blickensderfer; J H Best
Related Documents :
19331783 - Clinical implications of patent foramen ovale in migraine with aura.
17202093 - A multidisciplinary approach to carotid paragangliomas.
3408863 - Primary choice of intervention for distal ureteric stone: ureteroscopy or eswl?
Publication Detail:
Type:  JOURNAL ARTICLE     Date:  2014-7-21
Journal Detail:
Title:  Diabetes & metabolism     Volume:  -     ISSN:  1878-1780     ISO Abbreviation:  Diabetes Metab.     Publication Date:  2014 Jul 
Date Detail:
Created Date:  2014-7-25     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  9607599     Medline TA:  Diabetes Metab     Country:  -    
Other Details:
Languages:  ENG     Pagination:  -     Citation Subset:  -    
Copyright Information:
Published by Elsevier Masson SAS.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  The financial crisis, health and health inequities in Europe: the need for regulations, redistributi...
Next Document:  A Hunter Patient with a Severe Phenotype Reveals Two Large Deletions and Two Duplications Extending ...